- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01160796
Lcr35® for Bacterial Vaginosis Prevention
Study of the Efficacy and Safety of Treatment With Total Freeze-dried Culture of Lactobacillus Casei Var. Rhamnosus (Lcr35®) Administered Intravaginally in the Prevention of Bacterial Vaginosis. Randomized, Phase III, Multi-centre, Double-blind, Placebo-controlled Superiority Trial
This is a national, multi-centre, randomized, double-blind placebo-controlled, phase III superiority trial.
The main objective of the trial is to assess the efficacy of Lcr35® by comparing the mean time before the onset of the first clinical recurrence confirmed by laboratory tests in patients with bacterial vaginosis treated with Lcr35® versus placebo.
Patients with bacterial vaginosis will be enroll by private gynecologists. Each patient will receive a treatment for the initial episode(Metronidazole)and a treatment to prevent the recurrence of bacterial vaginosis (Lcr35®).
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Aurillac, France, 15000
- Lyocentre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient presenting with a symptomatic vaginosis characterised by the presence of the following 3 clinical criteria (among the 4 Amsel criteria) at V1:
- greyish uniform vaginal discharge,
- characteristic "rotten fish" smell caused by the spontaneous release of amine or during the potassium test or "sniff test",
- vaginal pH greater than 4.5.
- Patient with a Nugent score ≥ 7 (using the sample taken at V1).
- Patient clinically cured (none of the 3 Amsel criteria) after a 7-day course of Metronidazole (Flagyl®) Female.
- Patient over 18 years of age.
For women with childbearing potential:
- negative urine pregnancy test,
- use of a contraceptive method deemed effective by the Investigator (excluding spermicides).
- Patient having received information and voluntarily signed a written Informed Consent Form.
- Patient covered by a national insurance scheme.
Exclusion Criteria:
- Presence of a yeast infection that is bacterial (other than vaginosis) or viral in origin presumed or proven to be gynaecologically-linked, whether or not treated within the month preceding inclusion or present at the time of inclusion.
- Presence of an existing gynaecological infection that may interfere with the assessment of the trial treatment(fibroma, severe dysplasia of the cervix or in situ carcinoma, invasive carcinoma, intra-epithelial cervical neoplasia, squamous intra-epithelial lesions etc.)
- Antibiotics or antifungals taken by general route during the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis.
- Use of probiotics in the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis.
- Use of intravaginal antiseptics in the month preceding the screening visit, excluding treatment for an earlier episode of vaginosis.
- Use of prebiotics (acidifiers) during the two weeks preceding the screening visit.
- Use of products containing topical oestrogens during the month preceding the screening visit.
- Allergy to one of the active ingredients or one of the excipients in the products.
- patient in post-menopausal time
- Patient unable to comply with the constraints of the Protocol.
- Breastfeeding patient.
- Patient with menstrual bleeds lasting more than 12 days a month.
- Patient having taken part in a clinical trial in the 3 months preceding inclusion in the present Protocol.
- Patient with a severe acute or chronic disease deemed by the Investigator to be incompatible with participation in the trial, or a serious infection that is life-threatening in the short term.
- Immuno-suppressed patient.
- Patient presenting with a previous illness which, according to the Investigator, is likely to interfere with the results of the trial or expose the patient to an additional risk.
- Patient linguistically or mentally unable to understand and sign the Informed Consent Form.
- Patient deprived of her liberty by order of the Courts or civil authorities or subject to a guardianship order.
- Patient likely not to comply with treatment.
- Patient unable to be contacted in the case of an emergency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: placebo
|
1x14-day course of treatment during 4 cycles
|
EXPERIMENTAL: Lcr35®
|
1x14-day course of treatment during 4 cycles
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
mean time before the onset of first clinical recurrence confirmed by laboratory tests
Time Frame: 4 months
|
4 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PREVA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Vaginosis
-
Alfasigma S.p.A.ParexelTerminatedBACTERIAL VAGINOSISUnited States
-
CDA Research Group, Inc.TerminatedBacterial Vaginosis (BV)United States
-
University of Alabama at BirminghamWayne State UniversityCompletedRecurrent Bacterial VaginosisUnited States
-
Zagazig UniversityUnknownBacterial Vaginosis TreatmentEgypt
-
Unity Health TorontoCompleted
-
Zagazig UniversityRecruitingBacterial Vaginosis | Vaginal | MicrobiologyEgypt
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Mount Sinai Hospital, CanadaUnity Health TorontoCompletedPregnant Women Who Test Positive for Bacterial VaginosisCanada
-
Universiti Kebangsaan Malaysia Medical CentreNot yet recruitingBacterial Vaginoses
-
Kaiser PermanenteWithdrawnRecurrent Bacterial VaginosisUnited States
Clinical Trials on Lcr35®
-
Medical University of WarsawCompleted
-
University Hospital, Clermont-FerrandUniversité d'AuvergneTerminatedPseudomonas Infections
-
National Taiwan University HospitalCompleted
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Chong Kun Dang PharmaceuticalCompleted
-
Sanofi Pasteur, a Sanofi CompanyCompletedPertussis | Diphtheria | PolioUnited States
-
Chung-Ang University Hosptial, Chung-Ang University...UnknownFunctional DyspepsiaKorea, Republic of
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada
-
Novartis PharmaceuticalsCompletedPulmonary Disease, Chronic Obstructive (COPD)Argentina